tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsTools for Trading PlatformsData for Hedge FundsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

AVXL Stock Latest News

Anavex appoints Kun Jin as VP, head of biostatistics
The FlyAnavex appoints Kun Jin as VP, head of biostatistics
11d ago
AVXL
Anavex price target lowered to $28 from $35 at BTIG
The FlyAnavex price target lowered to $28 from $35 at BTIG
1M ago
AVXL
Anavex reports Q1 EPS (17c), consensus (19c)
The FlyAnavex reports Q1 EPS (17c), consensus (19c)
1M ago
AVXL
Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
Press ReleasesAnavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results
1M ago
AVXL
Anavex could submit blarcamesine to FDA by year end, says H.C. Wainwright
The FlyAnavex could submit blarcamesine to FDA by year end, says H.C. Wainwright
1M ago
AVXL
Anavex announces exceeding enrollment target for ANAVEX2-73 EXCELLENCE trial
The FlyAnavex announces exceeding enrollment target for ANAVEX2-73 EXCELLENCE trial
2M ago
AVXL
Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Press ReleasesAnavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
2M ago
AVXL
Anavex price target raised to $50 from $42 at H.C. Wainwright
The FlyAnavex price target raised to $50 from $42 at H.C. Wainwright
3M ago
AVXL
Anavex appoints Grimmer to Scientific Advisory Board
The FlyAnavex appoints Grimmer to Scientific Advisory Board
3M ago
AVXL
Anavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
Press ReleasesAnavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s Trial
3M ago
AVXL
Anavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
Press ReleasesAnavex Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
3M ago
AVXL
Unusually active option classes on open December 6th
The FlyUnusually active option classes on open December 6th
3M ago
CDE
CGC
Anavex downgraded to Neutral from Overweight at Cantor Fitzgerald
The FlyAnavex downgraded to Neutral from Overweight at Cantor Fitzgerald
3M ago
AVXL
Anavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
Press ReleasesAnavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022
4M ago
AVXL
Anavex Shoots Up After Positive Topline Data
Market NewsAnavex Shoots Up After Positive Topline Data
4M ago
AVXL
Anavex price target raised to $80 from $40 at JonesTrading
The FlyAnavex price target raised to $80 from $40 at JonesTrading
4M ago
AVXL
BIIB
ANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
Press ReleasesANAVEX®2–73 (Blarcamesine) Phase 2B/3 Study Met Primary and Key Secondary Endpoints, Showing Statistically Significant Reduction of Clinical Decline in Global Clinical Study of Patients With Early Alzheimer’s Disease
4M ago
AVXL
Anavex phase 2B/3 study of blarcamesine met primary and key secondary endpoints
The FlyAnavex phase 2B/3 study of blarcamesine met primary and key secondary endpoints
4M ago
AVXL
Anavex Stock: Volatility Beckons but the Pipeline Has Big Potential, Says Analyst
Stock Analysis & IdeasAnavex Stock: Volatility Beckons but the Pipeline Has Big Potential, Says Analyst
4M ago
AVXL
Anavex reports Q4 EPS (18c), consensus (16c)
The FlyAnavex reports Q4 EPS (18c), consensus (16c)
4M ago
AVXL
Anavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
Press ReleasesAnavex Life Sciences to Announce Fiscal 2022 Year End Financial Results on Monday November 28, 2022
4M ago
AVXL
Anavex management to meet with Piper Sandler
The FlyAnavex management to meet with Piper Sandler
4M ago
AVXL
Anavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
Press ReleasesAnavex Life Sciences Announces Late-Breaking Presentation of Phase 2b/3 Data of Oral ANAVEX®2-73 (blarcamesine) for Early Alzheimer’s Disease at the Upcoming Clinical Trials on Alzheimer’s Disease (CTAD) Congress 2022
5M ago
AVXL
Anavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
Press ReleasesAnavex Life Sciences Announces Issuance of U.S. Patent Covering ANAVEX®2-73 (blarcamesine) for Neurodevelopmental Disorders Therapy
6M ago
AVXL
Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer’s Disease
Press ReleasesAnavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer’s Disease
7M ago
AVXL
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
Press ReleasesAnavex Life Sciences Provides Business Update and Reports Fiscal 2022 Third Quarter Financial Results
7M ago
AVXL
Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Press ReleasesAnavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
8M ago
AVXL
Anavex Life Sciences Updates 2 Key Risk Factors
Market NewsAnavex Life Sciences Updates 2 Key Risk Factors
1y ago
AVXL
3 “Strong Buy” Stocks With Robust Upside Ahead
Stock Analysis & Ideas3 “Strong Buy” Stocks With Robust Upside Ahead
2y ago
AVXL
IMBI
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.